Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 177   

Articles published

AZN 5,158.00 -8.00 (-0.15%)
price chart
AstraZeneca rises as Credit Suisse praises recent progress, hikes price target ...
Shares in AstraZeneca PLC (LON:AZN) headed higher on Monday morning after the UK drugs giant was on the end of an upgrade from analysts at Credit Suisse.
AstraZeneca plc: US FDA accepts regulatory submission for Lynparza in ...
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the ...
Form 6-K ASTRAZENECA PLC For: Oct 17
AstraZeneca is committed to developing medicines to help every patient with lung cancer. We have two approved medicines and a growing pipeline that targets genetic changes in tumour cells and boosts the power of the immune response against cancer.
AstraZeneca's Imfinzi cancer drug clears another regulatory hurdle
AstraZeneca PLC's (LON:AZN) Imfinzi cancer treatment has cleared another regulatory hurdle after the US Food and Drug Administration accepted a supplemental Biologics License Application (sBLA) for the treatment of certain lung cancer patients.
AstraZeneca: FDA grants Imfinzi priority review  MarketWatch
AstraZeneca cancer drug gets FDA priority review
AstraZeneca PLC (AZN.LN) on Wednesday said that the U.S. Food & Drug Administration has granted a priority review to its new drug application for tablets that treat breast cancer.
Hutchison China MediTech, AstraZeneca Present Savolitinib Combo Data
LONDON (Alliance News) - Hutchison China MediTech Ltd said Tuesday it and AstraZeneca PLC presented safety and clinical data of combinations of savolitinib at the World Conference on Lung Cancer in Yokohama, Japan.
Chi-Med and AstraZeneca's Savolitinib Shows Encouraging Clinical ...  Business Wire (press release)
Hutchison China, AstraZeneca Say Drug Shows Potential to Treat Lung Cancer  Fox Business
Bernstein ups stance on AstraZeneca to 'outperform', citing big pipeline ...
US broker Bernstein has upped its stance on AstraZeneca PLC (LON:AZN) to 'outperform' from 'market perform, citing the drug maker's big pipeline and takeover possibilities.
4 Reasons To Buy, 2 Controversies Surrounding AstraZeneca  Benzinga
Why I'd buy AstraZeneca plc for fat dividends and pipeline potential
Healthcare titan AstraZeneca (LSE: AZN) has long been favoured by income-seeking investors, but some fear the company won't be able to replace blockbuster drugs that have lost patent protection.
AstraZeneca plc: Tagrisso granted breakthrough therapy designation by US FDA ...  The Wall Street Transcript
AstraZeneca's Tagrisso lung cancer drug granted 'breakthrough ...  Proactive Investors UK
AstraZeneca climbs as Bernstein backs takeover talk
AstraZeneca led the FTSE 100 higher on Friday after Bernstein Research said investors were wrong to write off the chances of another takeover approach.
AstraZeneca PLC (AZN) Key Indicators And Emerging Themes
AstraZeneca PLC (NYSE:AZN) gained 0.12% in yesterday's session, going up from its prior closing price of $34.61 to $34.65, and has now recorded rally in 3 consecutive sessions.
Astrazeneca PLC (NYSE:AZN) Stock Traded Higher Than Its 50 Day Average  First News 24